HEPATITIS C VIRUS GENOTYPE 1 Clinical Trials

17 clinical trials for HEPATITIS C VIRUS GENOTYPE 1 across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE LONG-TERM OUTCOMES WITH ABT-450/RITONAVIR/ABT-267 (ABT-450/R/ABT-267) AND ABT-333 WITH OR WITHOUT RIBAVIRIN (RBV) IN ADULTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (TOPAZ-I). — RECRUITING
• A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A 12- OR 8-WEEK TREATMENT REGIMEN OF SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR IN TREATMENT-NAÏVE AND -EXPERIENCED SUBJECTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS — RECRUITING · PHASE3
• A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A 12-WEEK REGIMEN OF SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR IN TREATMENT-NAÏVE OR -EXPERIENCED SUBJECTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS INFECTION AND CIRRHOSIS — RECRUITING · PHASE3
• A PHASE 3 EVALUATION OF A DACLATASVIR/ASUNAPREVIR/BMS-791325 FIXED DOSE COMBINATION (FDC) IN NON-CIRRHOTIC SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C — RECRUITING · PHASE3
• A PHASE 3 EVALUATION OF A DACLATASVIR/ASUNAPREVIR/BMS-791325 FIXED DOSE COMBINATION IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND ADVANCED FIBROSIS OR COMPENSATED CIRRHOSIS — RECRUITING · PHASE3
• "A PHASE 3 BLINDED RANDOMIZED STUDY OF PEGINTERFERON LAMBDA-1A AND RIBAVIRIN COMPARED TO PEGINTERFERON ALFA-2A AND RIBAVIRIN, EACH ADMINISTERED WITH TELAPREVIR IN SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C WHO ARE TREATMENT-NAIVE OR RELAPSED ON TREATMENT WITH PEGINTERFERON ALFA AND RIBAVIRIN." — RECRUITING · PHASE3
• AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF OMBITASVIR (OBV), PARITAPREVIR (PTV), RITONAVIR (RTV) WITH OR WITHOUT DASABUVIR (DSV) AND WITH OR WITHOUT RIBAVIRIN (RBV) IN PEDIATRIC SUBJECTS WITH GENOTYPE 1 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (ZIRCON) — NOT_YET_RECRUITING
• AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN TREATMENT-NAÏVE ADULTS WITH GENOTYPE 1B HEPATITIS C VIRUS (HCV) WITHOUT CIRRHOSIS (GARNET) — COMPLETED
• THE EFFECTS OF ANTI-VIRAL THERAPY ON THE CLINICAL STATUS, QUALITY OF LIFE, AND SURVIVAL OF PATIENTS WITH DECOMPENSATED CIRRHOSIS DUE TO HEPATITIS C GENOTYPE 1 INFECTION — COMPLETED
• A PHASE 2, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF 6 OR 8 WEEKS OF TREATMENT WITH SIMEPREVIR, DACLATASVIR AND SOFOSBUVIR IN TREATMENT-NAÏVE SUBJECTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION. — COMPLETED · PHASE2
• A PHASE II, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-3682 WITH EITHER MK-8742 OR MK-8408 IN SUBJECTS WITH CHRONIC HCV GT1, GT2, AND GT4 INFECTION — COMPLETED · PHASE2
• A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 — COMPLETED · PHASE3
• AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR/ABT-450/ RITONAVIR AND DASABUVIR IN ADULTS WITH GENOTYPE 1B CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AND CIRRHOSIS (TURQUOISE-III). — COMPLETED
• AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH RIBAVIRIN IN ADULTS WITH GENOTYPE 1 AND OMBITASVIR/PARITAPREVIR/RITONAVIR WITH RIBAVIRIN IN ADULTS WITH GENOTYPE 4 CHRONIC HEPATITIS C VIRUS INFECTION AND DECOMPENSATED CIRRHOSIS (TURQUOISE-CPB) — COMPLETED
• A MULTICENTER, OPEN-LABEL, PARTIALLY RANDOMIZED, PARALLEL-GROUP, ADAPTIVE DESIGN, PHASE II STUDY ON EFFICACY AND SAFETY OF DEB025/ALISPORIVIR IN COMBINATION WITH RG7128/MERICITABINE PLUS RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT-NAÏVE, GENOTYPE 3 PREVIOUS TREATMENT-FAILURE, AND GENOTYPE 3 CIRRHOTIC PATIENTS — NOT_YET_RECRUITING · PHASE2
• A PHASE 2, MULTICENTER, PARTIALLY RANDOMIZED, PARTIALLY BLIND, DOSE RANGING STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF VX 135 AND DACLATASVIR IN TREATMENT NAÏVE ADULT SUBJECTS WITH GENOTYPES 1 AND 3 CHRONIC HEPATITIS C. — NOT_YET_RECRUITING · PHASE2
• A PHASE II RANDOMISED, DOUBLE-BLIND AND PLACEBO-CONTROLLED STUDY OF BI 207127 IN COMBINATION WITH FALDAPREVIR AND RIBAVIRIN IN PATIENTS WITH MODERATE HEPATIC IMPAIRMENT (CHILD-PUGH B) WITH GENOTYPE 1B CHRONIC HEPATITIS C INFECTION — NOT_YET_RECRUITING · PHASE2

Refine this search